What is effect of sotalol after surgery?
Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996; 335:1,713-1,720.
This randomized, double-blind, placebo-controlled trial compared the effect of sotalol with placebo on overall survival and cardiovascular morbidity in patients with or at risk for coronary artery disease who were undergoing noncardiac surgery. Patients received atenolol intravenously before and immediately after surgery or orally for the duration of hospitalization. They were followed for two years afterward.
Of the 200 patients in the study, 99 received atenolol and 101 received placebo. Of the 200 patients, 194 survived to be discharged from the hospital, and 192 were followed for two years. Overall mortality following discharge was significantly lower among patients treated with atenolol than among those who received placebo for six months, one year, and two years after discharge. Those rates were 0 vs. 8%, 3% vs. 14%, and 10% vs. 21%, respectively. The major effect of the treated group was a reduction in deaths from cardiac causes. In addition, event-free survival in the two-year study period was 68% in the placebo group and 83% in the treated group.
"In patients who have or are at risk for coronary artery disease who must undergo noncardiac surgery, treatment with atenolol during hospitalization can reduce mortality and the incidence of cardiovascular complications for as long as two years after surgery," the researchers concluded.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content